Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor response

References

• Asundi J, Crocker L, Tremayne J, Chang P, Sakanaka C, Tanguay J, Spencer S, Chalasani S, Luis E, Gascoigne K, et al. An antibody-drug conjugate directed against lymphocyte antigen 6 complex, locus E (LY6E) provides robust tumor killing in a wide range of solid tumor malignancies. Clinical Cancer Research. 2015;21(14):3252–14. doi:10.1158/1078-0432.CCR-15-0156.
   PubMedGoogle Scholar
• Langford MB, Outhwaite JE, Hughes M, Natale DRC, Simmons DG. Deletion of the Syncytin A receptor Ly6e impairs syncytiotrophoblast fusion and placental morphogenesis causing embryonic lethality in mice. Scientific Reports. 2018;8(1):2083. doi:10.1038/s41598-018-22040-2.
   PubMedGoogle Scholar
• Yu J, Liu S-L. Emerging role of LY6E in virus–host interactions. Viruses [Internet]. 2019;11(11):1020–11. Available from https://www.mdpi.com/1999-4915/11/11/1020.
   Web of Science ®Google Scholar
• Lv Y, Song Y, Ni C, Wang S, Chen Z, Shi X, Jiang Q, Cao C, Zuo Y. Overexpression of lymphocyte antigen 6 complex, Locus E in gastric cancer promotes cancer cell growth and metastasis. Cell Physiology Biochem Int J Exp Cell Physiology Biochem Pharmacol. 2018;45(3):1219–29. doi:10.1159/000487453.
   PubMedGoogle Scholar
• Yeom CJ, Zeng L, Goto Y, Harada H. LY6E: a conductor of malignant tumor growth through modulation of the PTEN/PI3K/Akt/HIF-1 axis. Oncotarget. 2016:1–12. doi:https://doi.org/10.18632/oncotarget.11670
   Google Scholar
• Modi S, Eder JP, Lorusso P, Weekes C, Chandarlapaty S, Tolaney SM, McLaughlin J, Camidge DR, Chang C-W, Nazzal D, et al. A phase I study evaluating DLYE5953A, an antibody-drug conjugate targeting the tumor-associated antigen lymphocyte antigen 6 complex locus E (Ly6E), in patients (Pts) with solid tumors. Ann Oncol. 2016;27:vi114. doi:10.1093/annonc/mdw368.01.
   Google Scholar
• Tolaney SM, Do KT, Eder JP, LoRusso PM, Weekes CD, Chandarlaplaty S, Chang C-W, Chen S-C, Nazzal D, Schuth E, et al. A Phase I study of DLYE5953A, an anti-LY6E antibody covalently linked to monomethyl auristatin E, in patients with refractory solid tumors. Clin Cancer Res.. 2020;26(21):5588-97. doi:10.1158/1078-0432.CCR-20-1067.
   Google Scholar
• Polakis P. Antibody drug conjugates for cancer therapy. Pharmacological Reviews. 2015;68:3–19. doi:10.1124/pr.114.009373.
   Google Scholar
• Wang S, Lu S. 2013. DNA immunization. Curr Protoc Microbiol. 31(1):18.3.1-18.3.24. doi:10.1002/9780471729259.mc1803s31
   PubMedGoogle Scholar
• Syomin BV, Ilyin YV. Virus-like particles as an instrument of vaccine production. Mol Biol+. 2019;53(3):323–34. doi:10.1134/S0026893319030154.
   PubMed Web of Science ®Google Scholar
• Komlodi-Pasztor E, Sackett D, Wilkerson J, Fojo T. Mitosis is not a key target of microtubule agents in patient tumors. Nat Rev Clin Oncol. 2011;8(4):244–50. doi:10.1038/nrclinonc.2010.228.
   PubMed Web of Science ®Google Scholar
• Dornan D, Bennett F, Chen Y, Dennis M, Eaton D, Elkins K, French D, Go MAT, Jack A, Junutula JR, et al. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood. 2009;114:2721–29.
   PubMed Web of Science ®Google Scholar
• Collins D, Bossenmaier B, Kollmorgen G, Niederfellner G. Acquired resistance to antibody-drug conjugates. Cancers. 2019;11(3):394. doi:10.3390/cancers11030394.
   PubMed Web of Science ®Google Scholar
• García-Alonso S, Ocaña A, Pandiella A. Resistance to antibody–drug conjugates. Cancer Res. 2018;78(9):2159–65. doi:10.1158/0008-5472.CAN-17-3671.
   PubMed Web of Science ®Google Scholar
• Liu-Kreyche P, Shen H, Marino AM, Iyer RA, Humphreys WG, Lai LY. Lysosomal P-gp-MDR1 confers drug resistance of brentuximab vedotin and its cytotoxic payload monomethyl Auristatin E in tumor cells. Front Pharmacol. 2019;10:749. doi:10.3389/fphar.2019.00749.
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Pastan IH. The role of multidrug resistance efflux pumps in cancer: revisiting a JNCI publication exploring expression of the MDR1 (P-glycoprotein) gene. J Natl Cancer I. 2015;107(9):djv222. doi:10.1093/jnci/djv222.
   PubMedGoogle Scholar
• Flynn MJ, Zammarchi F, Tyrer PC, Akarca AU, Janghra N, Britten CE, Havenith CEG, Levy JN, Tiberghien A, Masterson LA, et al. ADCT-301, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting CD25-expressing hematological malignancies. Molecular Cancer Therapeutics. 2016;15(11):2709–21. doi:10.1158/1535-7163.MCT-16-0233.
   PubMed Web of Science ®Google Scholar
• Hartley JA, Flynn MJ, Bingham JP, Corbett S, Reinert H, Tiberghien A, Masterson LA, Antonow D, Adams L, Chowdhury S, et al. Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine. Scientific Reports. 2018;8(1):10479. doi:10.1038/s41598-018-28533-4.
   PubMedGoogle Scholar
• Su D, Chen J, Cosino E. Cruz-Chuh J dela, Davis H, Rosario GD, Figueroa I, Goon L, He J, Kamath AV, et al. Antibody–drug conjugates derived from cytotoxic seco -CBI-dimer payloads are highly efficacious in xenograft models and form protein adducts in vivo. Bioconjugate Chem. 2019;30:1356–70.
   PubMed Web of Science ®Google Scholar
• Phillips GDL, Li G, Guo J, Lau J, Yu S-F, Pillow T, Lee B-C, Sadowsky J, Schutten M, Fields C, et al. Abstract 1207: preclinical development of 2nd generation HER2-directed antibody-drug conjugates. 2016;76(14):1207–1207.doi:10.1158/1538-7445/AM2016-1207
   Google Scholar
• Wesolowska O, Paprocka M, Kozlak J, Motohashi N, Dus D, Michalak K. Human sarcoma cell lines MES-SA and MES-SA/Dx5 as a model for multidrug resistance modulators screening. Anticancer Res. 2005;25:383–89.
   PubMed Web of Science ®Google Scholar
• Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, Chen Y, Simpson M, Tsai SP, Dennis MS, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol. 2008;26(8):925–32. doi:10.1038/nbt.1480.
   PubMed Web of Science ®Google Scholar
• Yip V, Figueroa I, Latifi B, Masih S, Ng C, Leipold D, Kamath A, Shen B-Q. Anti-Ly6E-seco-CBI-dimer antibody-drug conjugate (ADC) that forms adduct with alpha-1-microglobulin (A1M) demonstrates slower systemic antibody clearance and reduced tumor distribution in animals. Drug Metab Dispos. 2021;49(1). doi:10.1124/dmd.120.000145
   Google Scholar
• Slaga D, Ellerman D, Lombana TN, Vij R, Li J, Hristopoulos M, Clark R, Johnston J, Shelton A, Mai E, et al. Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3. Science Translational Medicine. 2018;10(463):eaat5775. doi:10.1126/scitranslmed.aat5775.
   PubMedGoogle Scholar
• Hötzel I, Theil F-P, Bernstein LJ, Prabhu S, Deng R, Quintana L, Lutman J, Sibia R, Chan P, Bumbaca D, et al. A strategy for risk mitigation of antibodies with fast clearance. mAbs. 2014;4(6):753–60. doi:10.4161/mabs.22189.
   Google Scholar
• Hnatowich DJ. Recent developments in the radiolabeling of antibodies with iodine, indium, and technetium. Semin Nucl Med. 1990;20(1):80–91. doi:10.1016/S0001-2998(05)80178-3.
   PubMedGoogle Scholar
• Khongorzul P, Ling CJ, Khan FU, Ihsan AU, Zhang J. Antibody-drug conjugates: a comprehensive review. Mol Cancer Res Mcr. 2019;18:3–19. doi:10.1158/1541-7786.MCR-19-0582.
   PubMedGoogle Scholar
• Gravanis I, Tzogani K, Hennik P, Van, Graeff PD, Schmitt P, Mueller-Berghaus J, Salmonson T, Gisselbrecht C, Laane E, Bergmann L, et al. The european medicines agency review of brentuximab vedotin (adcetris) for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma or systemic anaplastic large cell lymphoma: summary of the scientific assessment of the committee for medicinal products for human use. Oncol. 2015;21:102–09.
   Google Scholar
• Amiri-Kordestani L, Blumenthal GM, Xu QC, Zhang L, Tang SW, Ha L, Weinberg WC, Chi B, Candau-Chacon R, Hughes P, et al. FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014;20(17):4436–41. doi:10.1158/1078-0432.CCR-14-0012.
   PubMed Web of Science ®Google Scholar
• Williams S, Kim M. Inotuzumab ozogamicin in relapsed or refractory B-cell acute lymphoblastic leukemia. J Adv Pract Oncol. 2018;9(6) 670-6.
   Google Scholar
• American Society of Health-System Pharmacists, Inc. Enfortumab Vedotin-ejfv. Am J Health-syst Ph. 2020;77(8):592–93. doi:10.1093/ajhp/zxaa018.
   Google Scholar
• Walter RB, Gooley TA. Velden VHJ van der, Loken MR, Dongen JJM van, Flowers DA, Bernstein ID, Appelbaum FR. CD33 expression and P-glycoprotein–mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood. 2007;109:4168–70.
   PubMed Web of Science ®Google Scholar
• Takeshita A, Shinjo K, Yamakage N, Ono T, Hirano I, Matsui H, Shigeno K, Nakamura S, Tobita T, Maekawa M, et al. CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma. Brit J Haematol. 2009;146(1):34–43. doi:10.1111/j.1365-2141.2009.07701.x.
   PubMed Web of Science ®Google Scholar
• Al-Rohil RN, Torres-Cabala CA, Patel A, Tetzlaff MT, Ivan D, Nagarajan P, Curry JL, Miranda RN, Duvic M, Prieto VG, et al. Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding: loss of CD30 expression after treatment with brentuximab vedotin. J Cutan Pathol. 2016;43(12):1161–66. doi:10.1111/cup.12797.
   PubMed Web of Science ®Google Scholar
• Goyal A, Patel S, Goyal K, Morgan EA, Foreman RK. Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin. J Cutan Pathol. 2019;46(11):823–29. doi:10.1111/cup.13545.
   PubMedGoogle Scholar
• Owonikoko TK, Hussain A, Stadler WM, Smith DC, Kluger H, Molina AM, Gulati P, Shah A, Ahlers CM, Cardarelli PM, et al. First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70. Cancer Chemoth Pharm. 2015;77(1):155–62. doi:10.1007/s00280-015-2909-2.
   PubMedGoogle Scholar
• Saura C, Thistlethwaite F, Banerji U, Lord S, Moreno V, MacPherson I, Boni V, Rolfo CD. Vries EGE de, Herpen CML-Vet al. A phase I expansion cohorts study of SYD985 in heavily pretreated patients with HER2-positive or HER2-low metastatic breast cancer. J Clin Oncol. 2018;36:1014–1014.
   Web of Science ®Google Scholar
• Chen R, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Klasa R, Connors JM, Engert A, Larsen EK, Kennedy DA, et al. Results of a pivotal phase 2 study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2010;116(21):283–283. doi:10.1182/blood.V116.21.283.283.
   Google Scholar
• Rosenberg JE, O’Donnell PH, Balar AV, McGregor BA, Heath EI, Yu EY, Galsky MD, Hahn NM, Gartner EM, Pinelli JM, et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. J Clin Oncol Official J Am Soc Clin Oncol. 2019;37(29):2592–600. doi:10.1200/JCO.19.01140.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Flinn IW, Advani R, Sehn LH, Diefenbach C, Kolibaba K, Press OW, Salles G, Tilly H, Chen AI, et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol. 2019;6(5):e254–65. doi:10.1016/S2352-3026(19)30026-2.
   PubMed Web of Science ®Google Scholar
• Morgensztern D, Besse B, Greillier L, Santana-Davila R, Ready N, Hann CL, Glisson BS, Farago AF, Dowlati A, Rudin CM, et al. Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing, relapsed/refractory small cell lung cancer: results from the phase II TRINITY study. Clin Cancer Res Official J Am Assoc Cancer Res. 2019;25(23):6958–66. doi:10.1158/1078-0432.CCR-19-1133.
   PubMed Web of Science ®Google Scholar
• Hicks SW, Tarantelli C, Wilhem A, Gaudio E, Li M, Arribas AJ, Spriano F, Bordone R, Cascione L, Lai KC, et al. The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models. Haematologica. 2019;104(8):1633–39. doi:10.3324/haematol.2018.211011.
   PubMedGoogle Scholar
• Bardia A, Mayer IA, Diamond JR, Moroose RL, Isakoff SJ, Starodub AN, Shah NC, O’Shaughnessy J, Kalinsky K, Guarino M, et al. Efficacy and safety of anti-trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer. Journal of Clinical Oncology. 2017;35(19):2141–48. doi:10.1200/JCO.2016.70.8297.
   PubMed Web of Science ®Google Scholar
• Thurber GM, Zajic SC, Wittrup KD. Theoretic criteria for antibody penetration into solid tumors and micrometastases. J Nucl Med. 2007;48(6):995–99. doi:10.2967/jnumed.106.037069.
   PubMed Web of Science ®Google Scholar
• Rudnick SI, Lou J, Shaller CC, Tang Y, Klein-Szanto AJP, Weiner LM, Marks JD, Adams GP. Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Res. 2011;71(6):2250–59. doi:10.1158/0008-5472.CAN-10-2277.
   PubMed Web of Science ®Google Scholar
• Edelman GM, Cunningham BA, Gall WE, Gottlieb PD, Rutishauser U, Waxdal MJ. The covalent structure of an entire gammaG immunoglobulin molecule. Proceedings of the National Academy of Sciences. 1969;63(1):78–85. doi:10.1073/pnas.63.1.78.
   PubMed Web of Science ®Google Scholar
• Safdari Y, Farajnia S, Asgharzadeh M, Khalili M. Antibody humanization methods - a review and update. Biotechnol Genet Eng. 2013;29(2):175–86. doi:10.1080/02648725.2013.801235.
   PubMed Web of Science ®Google Scholar
• Chen BK, Rousso I, Shim S, Kim PS. Efficient assembly of an HIV-1/MLV Gag-chimeric virus in murine cells. Proc National Acad Sci. 2001;98(26):15239–44. doi:10.1073/pnas.261563198.
   PubMedGoogle Scholar
• Théry C, Amigorena S, Raposo G, Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biology. 2006;30(1). 3.22.1-3.22.29. doi:10.1002/0471143030.cb0322s30.
   Google Scholar
• Tang D, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature. 1992;356(6365):152–54. doi:10.1038/356152a0.
   PubMed Web of Science ®Google Scholar
• Hansen DT, Robida MD, Craciunescu FM, Loskutov AV, Dörner K, Rodenberry J-C, Wang X, Olson TL, Patel H, Fromme P, et al. Polyclonal antibody production for membrane proteins via genetic immunization. Sci Rep-uk. 2016;6(1):21925. doi:10.1038/srep21925.
   PubMedGoogle Scholar
• Price PW, McKinney EC, Wang Y, Sasser LE, Kandasamy MK, Matsuuchi L, Milcarek C, Deal RB, Culver DG, Meagher RB. Engineered cell surface expression of membrane immunoglobulin as a means to identify monoclonal antibody-secreting hybridomas. J Immunol Methods. 2009;343(1):28–41. doi:10.1016/j.jim.2009.01.005.
   PubMedGoogle Scholar
• Vij R, Lin Z, Chiang N, Vernes J-M, Storek KM, Park S, Chan J, Meng YG, Comps-Agrar L, Luan P, et al. A targeted boost-and-sort immunization strategy using Escherichia coli BamA identifies rare growth inhibitory antibodies. Sci Rep-uk. 2018;8(1):7136. doi:10.1038/s41598-018-25609-z.
   PubMedGoogle Scholar
• Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, DeBlanc RL, Gearing RP, Bovee TD, Siegall CB, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003;21(7):778–84. doi:10.1038/nbt832.
   PubMed Web of Science ®Google Scholar
• Adhikari P, Zacharias N, Ohri R, Sadowsky J. Site-specific conjugation to Cys-engineered THIOMAB™ antibodies. In: Tumey LN, editor. Antibody-drug conjugates, methods and protocols. New York (NY): Humana; 2020. p. 51–69.
   Google Scholar
• Fourie-O’Donohue A, Chu PY, Chuh J, Dela C, Tchelepi R, Tsai SP, Tran JC, Sawyer WS, Su D, Ng C, et al. Improved translation of stability for conjugated antibodies using an in vitro whole blood assay. Mabs. 2020;12(1):1715705. doi:10.1080/19420862.2020.1715705.
   PubMed Web of Science ®Google Scholar
• Pinheiro J, Bornkamp B, Glimm E, Bretz F. Model‐based dose finding under model uncertainty using general parametric models. Stat Med. 2014;33(10):1646–61. doi:10.1002/sim.6052.
   PubMed Web of Science ®Google Scholar